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Abstract In search for novel molecular targets in benign pros-
tate hyperplasia (BPH), a PCR Array based screening of 84
genes was performed. Of those, expression of ZFP91 (ZFP91
zinc finger protein) was notably upregulated. Limited data
concerning the function of ZFP91 product show that it is a
potential transcription factor upregulated in human acute mye-
logenous leukemia and most recently found to be the non-
canonical NF-κB pathway regulator. In order to test this finding
on a larger number of samples, prostate specimens were obtain-
ed from patients undergoing adenomectomy for BPH (n =21),
and as a control, from patients undergoing radical cystectomy
for bladder cancer (prostates unchanged pathologically, n =18).
Similar studies were performed on cultured human prostate
cancer cell lines: LNCaP, DU145, 22Rv1, PC-3; as well as
normal prostate epithelial cells—PrEC. Methods employed
included: Human Obesity PCR Array (Qiagen), QPCR and
Western blotting. QPCR studies confirmed significant overex-
pression of ZFP91 in BPH samples. On a protein level, how-
ever, comparison between normal and BPH prostates revealed
insignificant differences. As for prostate cell lines examined, all
expressed ZFP91 mRNA. Western blotting analysis showed
markedly higher protein levels of ZFP91 in all cancer cell lines
in comparison with normal (PrEC) cells. In conclusion, the
upregulated ZFP91 mRNA in BPH, not accompanied by par-
allel changes in ZFP91 protein levels, together with ZFP91
protein abundance in prostate cancer cell lines suggest ZFP91
involvement in these prostate diseases.
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Introduction
Several lines of evidence show that prostate health could be
adversely affected by obesity [1]. Among other findings, it
was proven that obesity increases the risk of more aggressive
prostate cancer [2], prostate enlargement in men with local-
ized prostate cancer [3], and developing benign prostate hy-
perplasia (BPH) [4].
The starting point for this study was to analyze expression
of obesity-related genes in BPH tissue specimens compared to
control prostates. Using a PCR Array based screening of 84
genes, three genes with significantly changed expression
levels were found: ZFP91 zinc finger protein (ZFP91), inter-
leukin 1 receptor, type I (IL1R1 ) and tumor necrosis factor
(TNF ). However, after a conventional QPCR validation of the
results on a larger number of samples, only ZFP91 emerged as
potentially involved in prostate pathology. Surprisingly
enough, its presence on a “Human Obesity RT2 Profiler
PCR Array” was a coincidence, as until yet it has no known
association with obesity. Most probably it was because
ZFP91 is situated adjacent to ciliary neurotrophic factor re-
ceptor (CNTFR , an anorectic gene) on a 11 chromosome and a
co-transcribed mRNA of the two was found in testis, however
this transcript is thought to be non-coding (Gene ID: 386607).
ZFP91 encodes a 63.4 kDa nuclear protein with structural
motifs characteristic of transcription factor [5]. In mammals it
is expressed ubiquitously in various cell types and is known to
be highly conservative, e.g. according to NCBI human ZFP91
shares 92.6% homologywith mouse ZFP91 at DNA level and
90.8 % at protein level [6]. In 2003, Unoki et al. found ZFP91
expression to be markedly upregulated in mononuclear cells
from patients with acute myelogenous leukemia (AML) and in
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many neoplastic blood cell lines. Moreover, it was shown that
suppression of ZFP91 expression could increase cell apopto-
sis rate [5]. To date, proteomic based studies showed ZFP91
interaction with a few proteins. Firstly, with ARF tumor
suppressor (cyclin-dependent kinase inhibitor 2A, isoform
4), which is known for its induction of p53-dependent cell
death or growth arrest in response to activated oncogenes [7].
Secondly, with mitogen-activated protein kinase kinase kinase
14 (MAP3K14) also known as NF-κB-inducing kinase
(NIK)—a key kinase of the non-canonical (alternative)
NF-κB activation pathway [8]. Lastly, with the von Hippel–
Lindau tumor suppressor (pVHL) and the hypoxia inducible
factor-1α (HIF-1α)—playing an important role in cancer
malignancy and metastasis [9]. As for ZFP91 function, it is
recognized as an atypical E3 ubiquitin-protein ligase. It medi-
ates a K63-linked ubiquitination of MAP3K14, leading to its
stabilization and activation of the non-canonical NF-κB path-
way, serving as a selective regulator of this pathway target
genes expression [8, 10].
In 2008 Lee et al. patented potential therapeutic methods
employing ZFP91 functioning modifications. Their invention
was based on several novel findings regarding ZFP91 signif-
icance. Among them, finding that ZFP91 expression is up-
regulated by NF-κB binding to its promoter sequences in
ZFP91 5′ upstream region. On the other hand, ZFP91 over-
expression results in increased NF-κB activity, which is dose
dependent and dependent on MAP3K14 presence. Moreover,
ZFP91 possesses potent oncogenic properties confirmed in
several experiments [9].
The present study aimed to investigate ZFP91 expression
on mRNA and protein levels in specimens from human nor-
mal prostate and BPH. Furthermore, we analyzed pattern of
expression of studied mRNA and protein in prostate cancer
cell lines and normal prostate epithelial cells.
Materials and Methods
Prostate Tissue Specimens
Studies were performed on patients from the Department of
Urology and Urooncology, Poznan University of Medical
Sciences. Bioethical Committee of the University provided
consent for the study protocol and each participant signed an
informed consent form. Prostate tissue specimens were ob-
tained from patients undergoing adenomectomy for BPH, and
as a control, from patients undergoing radical cystectomy for
bladder cancer (prostate tissue unchanged pathologically).
Tissue samples from control prostates were taken from the
regions adjacent to the colliculus seminalis (in a preliminary
study no differences in studied genes expression were found
between this region and region adjacent to connective tissue
capsule). BPH samples were taken from the anterior
periurethral area. Material was conserved in RNALater
(Ambion, Austin, USA) and kept at −20 °C until used.
Cell Culture
Prostate cancer cell lines: LNCaP, DU145, PC-3 and 22Rv1
were obtained from American Type Culture Collection
(ATCC, Manassas, USA) and maintained in RPMI-1640
Medium (LNCaP and 22Rv1), F12K Medium (PC-3) and
Eagle’s Minimum Essential Medium (DU145). Media were
purchased from ATCC and supplemented with 10 % fetal
bovine serum and antibiotic/antimycotic solution. Normal
prostate epithelial cells (PrEC) were obtained from Lonza
(Walkersville, USA) and cultured in serum-free PrEGM
(Lonza). The cells were grown in 75 cm2 flasks at 37 °C in
a humidified atmosphere of 5 % CO2. The culture medium
was changed every day for PrEC cells and every 2 days for
other cell lines. When cells reached approximately 80 %
confluence, they were either subcultured or harvested by
0.25 % trypsin–EDTA. Harvested cells were frozen in
−80 °C for further analyses.
Total RNA and Protein Extraction
Total RNA was extracted by means of TRI reagent, using
additional Dounce homogenization for tissues, followed by a
standard procedure combined with RNA purification using
NucleoSpin RNA II kit (Macherey-Nagel Ltd., Oensingen,
Switzerland). RNA concentration and purity was determined
spectrophotometrically (NanoDrop, Thermo Scientific,
Waltham, USA). For each sample 1 μg of total RNA was
reversely transcribed using MMLV reverse transcriptase kit
(Novazym, Poznan, Poland) using Oligo dT (PE Biosystems,
Warrington, UK) as primers. The reaction was performed at
42.8 °C for 60 min (UNO II thermocycler, Biometra,
Goettingen, Germany).
Total protein was extracted using homogenization in
an ice-cold RIPA buffer with addition of Complete Mini
Protease Inhibitor Cocktail Tablets (Roche Diagnostics
Corporation, Indianapolis, USA). Afterwards, samples
were incubated with an agitation for an hour and cen-
trifuged at 20,000× g for 30 min to remove cell debris
(all at 4 °C). Protein concentration was determined by
Bradford method.
Quantitative PCR Array
Human Obesity RT2 Profiler PCR Array was purchased from
SuperArray Bioscience (SABioscience, Frederick, USA).
PCR was performed on 7900HT Fast RT Real-Time PCR
System (Applied Biosystems), according to the manufac-
turer’s instructions. For data analysis, the ΔΔCt method was
used with the aid of a Microsoft Excel spreadsheet containing
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algorithms provided by the manufacturer. Fold-changes were
then calculated and expressed as log-normalized ratios of
values from BPH/control tissues.
QPCR Analysis
Analyses were performed as described earlier [11–14].
Briefly, all primer sets were designed to span at least one
intron (Table 2). They were purchased from the Laboratory
of DNA Sequencing and Oligonucleotide Synthesis (Institute
of Biochemistry and Biophysics, Polish Academy of
Sciences, Warsaw, Poland). Real-time PCR was carried out
in a Roche LightCycler 2.0 (Roche) with software version
4.05. SYBR Green detection system was used based on
LightCycler FastStart DNA Master SYBR Green I mix
(Roche). PCR reactions were carried out in 20 μL mixtures,
containing 4 μL template cDNA, 0.2 μM of each gene-
specific primer and 3.5 mM of Mg2+ ions. The real-time
PCR program included a 10 min denaturation step to activate
the Taq DNA polymerase, followed by a three-step amplifi-
cation program: denaturation at 95.0 °C for 9 s, annealing at
58.0 °C for 5 s, and extension at 72.0 °C for 5 s. Specificity of
the reaction products was routinely checked by determination
of melting points (0.1 °C/s transition rate) and random sample
separation in a 2.5 % ethidium bromide/agarose gel (Fig. 1).
Templates not submitted to RT reaction served as negative
controls. Out of three reference genes examined: tubulin alpha
1b (TUBA1B), aminolevulinate, delta-, synthase (ALAS1)
and β2-microglobulin (B2M), two first were selected using
geNorm method as a reference to normalize data. Of note,
selected genes were one of 3 out of 16 proven to be the
most stable and useful for normalization purposes in
gene profiling studies of prostate tissues, both malignant
and not [15].
PCR efficiency was assessed by a serial dilution method.
Briefly, products of PCR reactions were separated in a 2.5 %
agarose gel and specific bands were extracted using a DNA
gel extraction kit (Millipore, Billerica, USA). The amount of
extracted DNA was estimated spectrophotometrically.
Extracted DNAwas diluted (10-fold serial dilutions) in order
to generate a standard curve for efficiency calculation
(LightCycler software version 4.05.).
Western Blot Analysis
Analyses were performed as described earlier [11–13, 16].
Briefly, for each sample, 20 μg of protein was separated in a
4–20% gradient SDS-polyacrylamide electrophoretic gel, and
transferred onto a PVDF membrane. Jurkat whole cell lysate
(sc-2204; Santa Cruz Biotechnology) served as a positive
control for ZFP91 detection. Transferred proteins were stained
with Ponceau S. Membranes were incubated in a blocking
buffer consisting of 5 % nonfat dry milk in TBST for 1 h,
followed by primary antibody incubation overnight at 4 °C
with rabbit anti-ZFP91 at 1:200 (sc-102172; Santa Cruz
Biotechnology) or rabbit anti-GAPDH at 1:2000 (#5174;
Cell Signaling Technology). Afterwards, membranes were
thoroughly washed and incubated with an anti-rabbit HRP-
linked antibody at 1:2000 (#7074; Cell Signaling Technology)
for 1 h at room temperature. After washing, membranes were
incubated with enhanced chemiluminescence (ECL Plus,
Amersham) detection reagents (5 min, room temperature)
and visualized on GelDoc-It Imaging System (UVP, Upland,
USA) with use of VisionWorks LS Software. Band detection
and quantification of band intensity was performed using
TotalLab (Nonlinear dynamics, Newcastle upon Tyne,
England).
Statistical Analysis and Data Presentation
GraphPad Prism version 5.00 (GraphPad Software, San
Diego, USA) was used to perform statistical analyses. All data
were expressed as means ± SD. Differences were considered
significant at p <0.05. For a more detailed description of
particular experiment statistics, see description below each
figure.
Results
Expression of ZFP91 mRNA and Protein Levels in Benign
Prostate Hyperplasia
A screening of 84 obesity-related genes was performed by a
quantitative PCR array (Table 1). Only three genes, namely
Fig. 1 Ethidium bromide-stained 2.5 % agarose gel showing cDNA
amplified with human ZFP91 zinc finger protein (ZFP91), interleukin 1
receptor, type I (IL1R1), tumor necrosis factor (TNF), tubulin alpha 1b
(TUBA1B) and aminolevulinate, delta-, synthase (ALAS1) specific
primers. Note presence of reaction products with the expected size:
ZFP91—190 bp, IL1R1—147 bp; TNF—263 bp, TUBA1B—135 bp,
ALAS1—167 bp. Lanes description: C control prostate, B BPH sample,
N negative control (no RT of the RNA). As a DNA size standard
O’RangeRuler 50 bp DNA Ladder (Fermentas) was used
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ZFP91 , IL1R1 and TNF, had mean expression changed over
threefold in BPH samples compared to control prostate tis-
sues. Their expression was further analyzed using classic real-
time QPCR (Table 2, Fig. 1) on a larger number of samples
(Fig. 2). Only ZFP91 gene expression was confirmed to be
upregulated significantly in BPH specimens.
In order to test this finding on a protein level, Western
blotting of ZFP91 protein was performed (Fig. 3). To our
knowledge this is the first study to confirm ZFP91 presence
in prostate tissue and, as shown in further sections, in
prostate normal and cancer cells. After quantification of
ZFP91 abundance in BPH and control samples using
GAPDH levels as a reference (Fig. 3), differences in
ZFP91 protein levels between two groups were found to
be insignificant, which stands in contrast to the mRNA levels
differences.
Expression of ZFP91 mRNA and Protein Levels in Prostate
Cancer Cell Lines
QPCR analyses of ZFP91 gene expression in cultured PrEC,
LNCaP, DU145, PC-3 and 22Rv1 cells (Fig. 4) revealed stable,
comparable expression in all cells studied. Normal PrEC cells
had moderately higher mRNA levels than cancer PC-3 cells.
However, ZFP91 expression in both PrEC and PC-3 cells did
not statistically differ from ZFP91 expression in the rest of the
cell lines studied.
Presence of the ZFP91 gene product in above mentioned
cell lines was confirmed by means of Western blotting
(Fig. 5). After quantification of ZFP91 abundance in cells
using GAPDH levels as a reference (Fig. 5), markedly higher
protein quantity was noted in all cancer cell lines comparing to
normal prostate epithelial cells (PrEC).
Table 1 Functional grouping of 84 obesity-related genes assessed by the quantitative PCR array (Human Obesity RT2 Profiler PCR Array;
SABioscience, Frederick, MD, USA)
Orexigenic genes
Neuropeptides and receptors: ADRA2B, AGRP, CNR1, GAL, GALR1, MCHR1 (GPR24), HCRT,
HCRTR1, NPY, NPY1R, NR3C1 (GRL), OPRK1, OPRM1.
Gut hormone and receptor: GHRL (Ghrelin / Obestatin), GHSR.
Anorectic genes
Neuropeptides and receptors: ATRN (Attractin), BDNF, BRS3, CALCA, CALCR, CARTPT (CART), CNTFR,
CRHR1, DRD1, DRD2, GH1, GH2, GHR, NMUR1 (GPR66), GRP, GRPR,
HRH1, HTR2C, IL1A, IL1B, IL1R1 , IL6, IL6R, MC3R, NMB, NMBR, NMU,
NTRK2, NTS, NTSR1, PRLHR (GPR10), POMC, SORT1, TRH, UCN, ZFP91 .
Gut hormones and receptors: APOA4, CCK, CCKAR, GLP1R, PYY.
Adipocyte-derived peptides and receptors: LEP (Leptin), LEPR, TNF.
Pancreas derived peptides and receptors: CALCR, CLPS, GCG, GCGR, GLP1R, IAPP, INS, INSR, RAMP3, SST, SSTR2.
Genes related to energy expenditure
Adipocyte-derived peptides and receptors: ADIPOQ (ACRP30), ADIPOR1, ADIPOR2, ADRB1, C3, PPARA, PPARG,
PPARGC1A, PTPN1, UCP1.
CNS-derived peptides and receptors: ADCYAP1, ADCYAP1R1, CPD, CPE, SIGMAR1, THRB.
Genes rendered in italics had mean expression over threefold upregulated (ZFP91 and IL1R1) or downregulated (TNF) in BPH samples relative to
control prostate tissues (each group n=3)
Table 2 Conventional real-time QPCR analyses of ZFP91 zinc finger protein (ZFP91), interleukin 1 receptor, type I (IL1R1) and tumor necrosis factor
(TNF) genes expression
cDNA Genbank accession no. Primer Primer sequence (5′-3′) Position PCR product size (bp)
ZFP91 NM_053023 S TGTCCTTGCCCATCCTCGCTA 1128–1148 190
A ACTCTTGAAGGCCCGAGCAC 1298–1317
IL1R1 NM_000877 S CCAGCTAATGAGACAATGGA 773–792 147
A GTAATAGTCTTCCCCTAGCA 900–919
TNF NM_000594 S GCCTCTTCTCCTTCCTGATCGT 276–297 263
A ATCTCTCAGCTCCACGCCAT 519–538
TUBA1B NM_006082 S TGGAACCCACAGTCATTGATGA 430–451 135
A TGATCTCCTTGCCAATGGTGTA 543–564
ALAS1 NM_000688 S AGACATAACATCTACGTGCAA 2031–2051 167
A GAATGAGGCTTCAGTTCCA 2179–2197
Oligonucleotide sequences for sense (S) and antisense (A) primers are shown. Tubulin alpha 1b (TUBA1B) and aminolevulinate, delta-, synthase
(ALAS1) served as reference genes
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Discussion
Our study is the first to investigate ZFP91 expression at the
protein level in normal and pathologically changed prostate
tissues and cells. Until now, knowledge regarding ZFP91 ex-
pression in prostate was limited to Northern blot confirmation of
mRNA transcript presence in prostate [5], and finding of in-
creased mRNA expression levels in prostate cancer specimens
compared to unchanged prostate (by in situ hybridization) [9].
In our material a significant upregulation of ZFP91 mRNAwas
found in BPH samples, but it was not accompanied by changes
Fig. 2 QPCR analyses of ZFP91 , IL1R1 and TNF expression in BPH
(benign prostate hyperplasia) samples and control human prostates
(CONTROL). Bars represent mRNA levels relative to reference genes.
Mean expression in CONTROL was assigned a value of 100 for each
gene independently. Results are presented as means ± SD; CONTROL
n =18, BPH n =21. Statistical comparison by Mann–Whitney test; *p<
0.05, ns not significant
Fig. 3 Representative experiment of ZFP91 protein immunoblotting in
control prostates (CONTROL) and benign prostate hyperplasia samples
(BPH). Bars represent protein expression relative to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) levels. Results are presented as
means ± SD; each group n =14. Statistical comparison by Student’s t-
test; *p <0.05, ns not significant
Fig. 4 QPCR analyses of ZFP91 expression in cultured PrEC, LNCaP,
DU145, PC-3 and 22Rv1 cells. Bars represent mRNA levels relative to
reference genes. Mean expression in PrEC cells was assigned a value of
100 and normalized in other cell lines accordingly. Results are presented
as means ± SD; each group n =6. Statistical comparison by ANOVA
followed by Tukey’s test; *p <0.05
Fig. 5 Representative experiment of ZFP91 protein immunoblotting in
cultured PrEC, LNCaP, DU145, PC-3 and 22Rv1 cells. Bars represent
protein expression relative to glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) levels. Mean expression in PrEC cells was assigned a
value of 100 and normalized in other cell lines accordingly. Results are
presented as means ± SD; each group n =6. Statistical comparison by
ANOVA followed by Tukey’s test; *p <0.05
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in protein levels. On the other hand, prostate cancer cell lines
and normal prostate epithelial cells had similar ZFP91 mRNA
levels; however protein abundance was clearly the highest in
cancer cell lines. This may correspond to Lee et al. 2008
observation that ZFP91 expression induction by NF-κB path-
way activators resulted in limited changes at mRNA level but
significant and time-dependent at protein level.
Phenomenon of poor correlation between mRNA and pro-
tein abundance is well known in the field of gene expression
analysis [17–20]. For instance, a study in lung adenocarci-
nomas showed that only about one fifth of investigated genes
expression had significant correlation between protein and
mRNA levels [21]. Although mRNA concentration is one of
the important factors determining protein abundance, several
other factors also influence mRNA/protein ratio. A reasonable
approach to this issue is to assume that mRNA levels can be
used as surrogates for corresponding protein levels, but not
without verification. Results of this study show, that in case of
ZFP91 expression no clear correlation between mRNA and
protein levels exist.
Taking into account ZFP91 potential function as a tran-
scription factor and/or cell-cycle regulator, one can hypothe-
size that it is a protein with a fast turnover rate, subjected to
rapid intracellular degradation. ZFP91 relatively high abun-
dance in cancer cells could result from its greater stability and
accumulation in these cells. Such phenomenon was observed
for many oncogenic proteins, for instance p53 which abun-
dance depends on posttranscriptional regulations [22].
Moreover, many factors in NF-κB signaling pathway are
subjected to strict expression control by e.g. targeting to
proteasomal degradation [23]. ZFP91 could be one of such
factors in this pathway.
NF-κB is a protein complex of transcription factors partic-
ipating in a range of biological processes, among them cell
growth and development, cell survival and inflammatory re-
sponses. NF-κB activation results in either canonical or non-
canonical (alternative) NF-κB pathway signalling, or both.
Non-canonical NF-κB pathway is associated with several im-
portant biological functions including lymphoid malignancies.
An important feature of this pathway is its strict dependence on
MAP3K14 protein level, which is controlled mainly through its
ubiquitin-dependent degradation. In this regard it should be
underlined that ZFP91 serves as a positive regulator for
MAP3K14, causing its stabilization and activation [24, 25].
Furthermore, oncogenic activity of the MAP3K14 protein is
postulated. Its overexpression has been associated with neo-
plastic growth e.g. in melanoma, pancreatic carcinoma, breast
cancer, lung cancer, multiple myeloma and adult T-cell leuke-
mia. ZFP91-mediated stabilization may stand for one of mech-
anisms of MAP3K14 oncogenic activation [26].
In prostate cancer, clinical data and results from in vitro
experiments imply that the NF-κB system is capable of inter-
fering with androgen receptor (AR) signaling. AR interaction
with NF-κB factor p52 (involved in non-canonical pathway)
has a positive effect on cell growth, cell survival and AR target
genes expression [27]. In the light of our studies it seems
legitimate to suggest that ZFP91 functioning may influence
androgen-dependent genes expression and prostate cancer
biology.
Regarding ZFP91 oncogenic potential, several experiments
besides already mentioned highlight its importance. Firstly,
cancer cell lines overexpressing ZFP91 had an increased col-
ony formation potential and invasiveness. Secondly, tumors
induced in nude mice by ZFP91 overexpressing cancer cells
had overall faster growth rate and higher angiogenic potential.
Lastly, ZFP91 suppression by RNA interference resulted in
decreased levels of antiapoptotic proteins and increased apo-
ptosis rate [9]. Furthermore, ZFP91 was found to be
overexpressed in malignant breast cancer and stomach cancer
cell lines having high NF-κB activity in comparison with cell
lines having lower NF-κB activity [9]. In studies concerning
prostate pathology, NF-κB was constitutively activated in hu-
man androgen-insensitive prostate cancer cell lines such as
DU145, and PC-3, but not in LNCaP androgen-sensitive cells
or normal PrEC cells [28]. Our study showed however, that
ZFP91 expression does not differ between DU145, PC-3 and
LNCap cell lines. This suggests that above mentioned relation
between basal NF-κB activity and ZFP91 expression should
not be generalized.
As far as the results of the present study are concerned, the
role of upregulated ZFP91 mRNA in BPH prostates, not
accompanied by parallel changes in ZFP91 protein levels, is
still to be explored. On the other hand, ZFP91 relative abun-
dance in prostate cancer cells, together with the promising
field of ZFP91 potential interactions, makes it a novel inter-
esting target of studies. Presented work provides a base for
further experiments aiming at characterizing ZFP91 role in
prostate pathology.
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